Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction

Ruey Hsing Chou, Po Hsun Huang, Chien Yi Hsu, Chun Chin Chang, Hsin Bang Leu, Chin Chou Huang, Jaw Wen Chen, Shing Jong Lin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Fibroblast growth factor 21 (FGF21), a polypeptide ligand promoted glucose homeostasis and lipids metabolism, was recently reported to attenuate cardiac hypertrophy. The aim of this study was to investigate the impact of FGF21 in diastolic heart failure. Subjects admitted for coronary angiogram were screened for heart failure, and those with left ventricular (LV) ejection fraction < 45% were excluded. Diastolic dysfunction was defined as functional abnormalities that exist during LV relaxation and filling by echocardiographic criteria. Plasma levels of FGF21 and N-terminal Pro-Brain Natriuretic Peptide (NT-pro-BNP) were determined. All patients were followed up for 1 year, or till the occurrence of heart failure readmission or death. Totally 95 patients with diastolic dysfunction and 143 controls were enrolled. Circulating FGF21 level was correlated with echocardiographic parameters of diastolic function and LV end-diastolic pressure (LVEDP). In multivariate logistic analysis, FGF21 was significantly associated with diastolic dysfunction, either identified by echocardiographic criteria (odds ratio: 2.97, p = 0.012) or confirmed with LVEDP level (odds ratio: 3.73, p = 0.030). Both plasma FGF21 (log rank p < 0.0001) and NT-pro-BNP levels (log rank p = 0.0057) showed good predictive power to the 1-year adverse cardiac events. This finding suggested FGF21 could be involved in the pathophysiology of diastolic heart failure.

Original languageEnglish
Article number33953
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Sep 21 2016

Fingerprint

Heart Failure
Diastolic Heart Failure
Brain Natriuretic Peptide
Odds Ratio
Blood Pressure
Cardiomegaly
fibroblast growth factor 21
Lipid Metabolism
Left Ventricular Function
Stroke Volume
Angiography
Homeostasis
Multivariate Analysis
Ligands
Glucose
Peptides

ASJC Scopus subject areas

  • General

Cite this

Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. / Chou, Ruey Hsing; Huang, Po Hsun; Hsu, Chien Yi; Chang, Chun Chin; Leu, Hsin Bang; Huang, Chin Chou; Chen, Jaw Wen; Lin, Shing Jong.

In: Scientific Reports, Vol. 6, 33953, 21.09.2016.

Research output: Contribution to journalArticle

Chou, Ruey Hsing ; Huang, Po Hsun ; Hsu, Chien Yi ; Chang, Chun Chin ; Leu, Hsin Bang ; Huang, Chin Chou ; Chen, Jaw Wen ; Lin, Shing Jong. / Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. In: Scientific Reports. 2016 ; Vol. 6.
@article{fef6ae52abbf412c9ce388c5369666a8,
title = "Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction",
abstract = "Fibroblast growth factor 21 (FGF21), a polypeptide ligand promoted glucose homeostasis and lipids metabolism, was recently reported to attenuate cardiac hypertrophy. The aim of this study was to investigate the impact of FGF21 in diastolic heart failure. Subjects admitted for coronary angiogram were screened for heart failure, and those with left ventricular (LV) ejection fraction < 45{\%} were excluded. Diastolic dysfunction was defined as functional abnormalities that exist during LV relaxation and filling by echocardiographic criteria. Plasma levels of FGF21 and N-terminal Pro-Brain Natriuretic Peptide (NT-pro-BNP) were determined. All patients were followed up for 1 year, or till the occurrence of heart failure readmission or death. Totally 95 patients with diastolic dysfunction and 143 controls were enrolled. Circulating FGF21 level was correlated with echocardiographic parameters of diastolic function and LV end-diastolic pressure (LVEDP). In multivariate logistic analysis, FGF21 was significantly associated with diastolic dysfunction, either identified by echocardiographic criteria (odds ratio: 2.97, p = 0.012) or confirmed with LVEDP level (odds ratio: 3.73, p = 0.030). Both plasma FGF21 (log rank p < 0.0001) and NT-pro-BNP levels (log rank p = 0.0057) showed good predictive power to the 1-year adverse cardiac events. This finding suggested FGF21 could be involved in the pathophysiology of diastolic heart failure.",
author = "Chou, {Ruey Hsing} and Huang, {Po Hsun} and Hsu, {Chien Yi} and Chang, {Chun Chin} and Leu, {Hsin Bang} and Huang, {Chin Chou} and Chen, {Jaw Wen} and Lin, {Shing Jong}",
year = "2016",
month = "9",
day = "21",
doi = "10.1038/srep33953",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction

AU - Chou, Ruey Hsing

AU - Huang, Po Hsun

AU - Hsu, Chien Yi

AU - Chang, Chun Chin

AU - Leu, Hsin Bang

AU - Huang, Chin Chou

AU - Chen, Jaw Wen

AU - Lin, Shing Jong

PY - 2016/9/21

Y1 - 2016/9/21

N2 - Fibroblast growth factor 21 (FGF21), a polypeptide ligand promoted glucose homeostasis and lipids metabolism, was recently reported to attenuate cardiac hypertrophy. The aim of this study was to investigate the impact of FGF21 in diastolic heart failure. Subjects admitted for coronary angiogram were screened for heart failure, and those with left ventricular (LV) ejection fraction < 45% were excluded. Diastolic dysfunction was defined as functional abnormalities that exist during LV relaxation and filling by echocardiographic criteria. Plasma levels of FGF21 and N-terminal Pro-Brain Natriuretic Peptide (NT-pro-BNP) were determined. All patients were followed up for 1 year, or till the occurrence of heart failure readmission or death. Totally 95 patients with diastolic dysfunction and 143 controls were enrolled. Circulating FGF21 level was correlated with echocardiographic parameters of diastolic function and LV end-diastolic pressure (LVEDP). In multivariate logistic analysis, FGF21 was significantly associated with diastolic dysfunction, either identified by echocardiographic criteria (odds ratio: 2.97, p = 0.012) or confirmed with LVEDP level (odds ratio: 3.73, p = 0.030). Both plasma FGF21 (log rank p < 0.0001) and NT-pro-BNP levels (log rank p = 0.0057) showed good predictive power to the 1-year adverse cardiac events. This finding suggested FGF21 could be involved in the pathophysiology of diastolic heart failure.

AB - Fibroblast growth factor 21 (FGF21), a polypeptide ligand promoted glucose homeostasis and lipids metabolism, was recently reported to attenuate cardiac hypertrophy. The aim of this study was to investigate the impact of FGF21 in diastolic heart failure. Subjects admitted for coronary angiogram were screened for heart failure, and those with left ventricular (LV) ejection fraction < 45% were excluded. Diastolic dysfunction was defined as functional abnormalities that exist during LV relaxation and filling by echocardiographic criteria. Plasma levels of FGF21 and N-terminal Pro-Brain Natriuretic Peptide (NT-pro-BNP) were determined. All patients were followed up for 1 year, or till the occurrence of heart failure readmission or death. Totally 95 patients with diastolic dysfunction and 143 controls were enrolled. Circulating FGF21 level was correlated with echocardiographic parameters of diastolic function and LV end-diastolic pressure (LVEDP). In multivariate logistic analysis, FGF21 was significantly associated with diastolic dysfunction, either identified by echocardiographic criteria (odds ratio: 2.97, p = 0.012) or confirmed with LVEDP level (odds ratio: 3.73, p = 0.030). Both plasma FGF21 (log rank p < 0.0001) and NT-pro-BNP levels (log rank p = 0.0057) showed good predictive power to the 1-year adverse cardiac events. This finding suggested FGF21 could be involved in the pathophysiology of diastolic heart failure.

UR - http://www.scopus.com/inward/record.url?scp=84988838463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988838463&partnerID=8YFLogxK

U2 - 10.1038/srep33953

DO - 10.1038/srep33953

M3 - Article

C2 - 27650781

AN - SCOPUS:84988838463

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 33953

ER -